Clinical Scorecard: Trends and Developments in Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease Research: A Bibliometric Study (2005-2024)

At a Glance

Key Highlights

• Substantial increase in publications from 2005 to 2024, with 9,821 publications identified.
• The United States leads in research output, followed by China and Italy.
• Emerging research focuses on gut microbiota and lifestyle interventions.
• NAFLD is recognized as a hepatic manifestation of MetS.
• New nomenclature proposed for NAFLD as MAFLD emphasizes metabolic dysfunction.

Guideline-Based Recommendations

Diagnosis

• Adoption of new nomenclature: metabolic dysfunction-associated fatty liver disease (MAFLD).

Management

• Focus on early identification of high-risk factors to halt progression of MAFLD and MetS.

Monitoring & Follow-up

• Systematic mapping of associations between MAFLD and MetS.

Risks

• Increased risk of type 2 diabetes mellitus, cardiovascular diseases, and stroke.

Patient & Prescribing Data

Individuals with metabolic syndrome and non-alcoholic fatty liver disease.

Lifestyle interventions and mechanism-based precise diagnosis are critical.

Clinical Best Practices

• Utilize bibliometric analysis to identify research trends and gaps.
• Integrate findings on gut-liver axis in clinical assessments.
• Emphasize the role of metabolic dysfunction in liver disease management.

Related Resources & Content